Extended release of neuregulin for treating heart failure
View Patent ↗The present invention provides methods and kits for preventing, treating or delaying various cardiovascular diseases or disorders especially heart failure by extended release of neuregulin to a mammal. Moreover, the extended release of neuregulin is administered by subcutaneous infusion with a pump.
1. A method for treating chronic heart failure in a mammal, the method comprising administering subcutaneous extended release of neuregulin into a mammal in an amount of 0.3 μg/kg/day to 3.0 μg/kg/day, wherein the subcutaneous extended release of neuregulin into a mammal is accomplished through the use of a pump.
2. The method of claim 1 , wherein the mammal is human.
3. The method of claim 1 , wherein the subcutaneous extended release of neuregulin into a mammal is accomplished through the use of a syringe pump.
4. The method of claim 3 , wherein the syringe pump is a mini pump.
5. The method of claim 4 , wherein the mini pump is an insulin pump.
6. The method of claim 1 , wherein neuregulin is in an amount of 1.2 μg/kg/day to 2.0 μg/kg/day.
7. The method of claim 1 , wherein neuregulin is in an amount of 1.2 μg/kg/day.
8. The method of claim 1 , wherein neuregulin is in an amount of 2.0 μg/kg/day.
9. The method of claim 1 , wherein neuregulin is in an amount of 6 EU/kg/day to 60 EU/kg/day.
10. The method of claim 1 , wherein neuregulin is in an amount of 24 EU/kg/day to 40 EU/kg/day.
11. The method of claim 1 , wherein neuregulin is in an amount of 24 EU/kg/day.
12. The method of claim 1 , wherein neuregulin is in an amount of 40 EU/kg/day.
13. The method of claim 1 , wherein the neuregulin is administered to the mammal for an introduction regimen.
14. The method of claim 13 , wherein the introduction regimen includes an administration of neuregulin for at least 3, 5, 7, 10 or 15 consecutive days.
15. The method of claim 13 , wherein the introduction regimen includes an administration of neuregulin for 10 consecutive days.
16. The method of claim 13 , wherein the neuregulin is administered for at least 2, 4, 6, 8, 10, 12, 16, 20, 24 consecutive hours every day.
17. The method of claim 13 , wherein the neuregulin is administered for 8 consecutive hours every day.
18. The method of claim 13 , wherein the neuregulin is administered to the patients for a maintenance regimen after the introduction regimen.